nach oben

Die Onkologie

Erschienen in:

14.07.2019 | Plattenepithelkarzinom der Haut | CME

Plattenepithelkarzinom der Haut

verfasst von: Andreas Meiwes, Prof. Dr. Ulrike Leiter

Erschienen in: Die Onkologie | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Plattenepithelkarzinom (PEK) der Haut ist der zweithäufigste maligne Hauttumor. Aktuell macht es ca. 20 % aller nichtmelanozytären Hauttumoren aus und tritt am häufigsten an sonnenexponierten Stellen auf. Fortgeschrittene PEK entwickeln sich bei 5–20 % der Patienten. Risikofaktoren sind: Tumordicke >6 mm, -durchmesser ≥2 cm, histologische Differenzierung >Grad 3, Desmoplasie, perineurales Wachstum, Lokalisation, Immunsuppression. Eine histologische Sicherung klinisch verdächtiger Läsionen ermöglicht eine prognostische Einschätzung und korrekte Behandlung. Therapie der Wahl ist die operative Resektion. Die PEK können Lokalrezidive, Lymphknotenmetastasen sowie selten Fernmetastasen bilden. Bei fortgeschrittenen PEK sind Anti-PD-1-Inhibitoren (PD-1: „programmed cell death protein 1“) vielversprechend, die Zulassung wird in Kürze erwartet. Auch EGFR-Inhibitoren (EGFR: Rezeptor des epidermalen Wachstumsfaktors) sowie Chemotherapeutika werden eingesetzt. Es existiert kein Standardregime. Die Nachsorge sollte sich am jeweiligen Risiko orientieren.

Katalinic A, Kunze U, Schafer T (2003) Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 149(6):1200–1206PubMedCrossRef

Augustin J et al (2018) Epidemiology of skin cancer in the German population: impact of socioeconomic and geographic factors. J Eur Acad Dermatol Venereol 32(11):1906–1913PubMedCrossRef

Raasch BA, Buettner PG (2002) Multiple nonmelanoma skin cancer in an exposed Australian population. Int J Dermatol 41(10):652–658PubMedCrossRef

Brantsch KD et al (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9(8):713–720PubMedCrossRef

Leiter U et al (2017) Incidence, mortality, and trends of nonmelanoma skin cancer in Germany. J Invest Dermatol 137(9):1860–1867PubMedCrossRef

El Ghissassi F et al (2009) A review of human carcinogens—part D: radiation. Lancet Oncol 10(8):751–752PubMedCrossRef

Ulrich C et al (2003) Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol 149(Suppl 66):40–42PubMedCrossRef

Lott DG et al (2010) Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 90(6):683–687PubMedCrossRef

Leiter U, Eigentler T, Garbe C (2014) Epidemiology of skin cancer. Adv Exp Med Biol 810:120–140PubMed

10.

Douki T, von Koschembahr A, Cadet J (2017) Insight in DNA repair of UV-induced pyrimidine dimers by chromatographic methods. Photochem Photobiol 93(1):207–215PubMedCrossRef

11.

Chan TA et al (2018) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. https://doi.org/10.1093/annonc/mdy495 PubMedPubMedCentralCrossRef

12.

Harwood CA et al (2013) A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant 13(1):119–129PubMedCrossRef

13.

Thompson AK et al (2016) Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 152(4):419–428PubMedPubMedCentralCrossRef

14.

Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348(17):1681–1691PubMedCrossRef

15.

Berg D, Otley CC (2002) Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 47(1):1–17 (quiz 18–20)PubMedCrossRef

16.

Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65(2):253–261 (quiz 262)CrossRef

17.

Silverberg MJ et al (2013) HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 105(5):350–360PubMedPubMedCentralCrossRef

18.

Peleva E et al (2018) Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol 178(1):103–113PubMedCrossRef

19.

Becquart O et al (2019) Hydrochlorothiazide use and risk of skin cancers: A systematic review. Rev Med Interne. https://doi.org/10.1016/j.revmed.2019.04.008 PubMedCrossRef

20.

Martinez JC, Cook JL (2007) High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection? Dermatol Surg 33(4):410–420PubMed

21.

Leiter U, Garbe C (2008) Epidemiology of melanoma and nonmelanoma skin cancer—the role of sunlight. Adv Exp Med Biol 624:89–103PubMedCrossRef

22.

Farasat S et al (2011) A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 64(6):1051–1059PubMedPubMedCentralCrossRef

23.

Karia PS et al (2018) Comparison of tumor classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th vs 8th edition of the AJCC cancer staging manual. JAMA Dermatol 154(2):175–181PubMedCrossRef

24.

Togsverd-Bo K et al (2015) Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients—a randomized controlled trial. Br J Dermatol 172(2):467–474PubMedCrossRef

25.

Silberstein E et al (2015) Lymph node metastasis in cutaneous head and neck squamous cell carcinoma. Dermatol Surg 41(10):1126–1129PubMedCrossRef

26.

Wong WK, Morton RP (2014) Elective management of cervical and parotid lymph nodes in stage N0 cutaneous squamous cell carcinoma of the head and neck: a decision analysis. Eur Arch Otorhinolaryngol 271(11):3011–3019PubMedCrossRef

27.

Gurney B, Newlands C (2014) Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma. Br J Oral Maxillofac Surg 52(4):294–300PubMedCrossRef

28.

Canueto J, Roman-Curto C (2017) Novel additions to the AJCC’s new staging systems for skin cancer. Actas Dermosifiliogr 108(9):818–826PubMedCrossRef

29.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3 Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut, Langversion 0.1(Konsultationsfassung).

30.

Renzi C et al (2007) Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol 33(3):364–369PubMedCrossRef

31.

Maruyama H et al (2017) Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma. J Dermatol 44(4):431–437PubMedCrossRef

32.

Dantal J et al (2018) Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5‑year results. J Clin Oncol 36(25):2612–2620PubMedCrossRef

33.

Mendenhall WM et al (2007) Skin cancer of the head and neck with perineural invasion. Am J Clin Oncol 30(1):93–96PubMedCrossRef

34.

Palmer JD et al (2018) Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis. Oral Oncol 78:102–107PubMedCrossRef

35.

Veness MJ et al (2005) Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 115(5):870–875PubMedCrossRef

36.

Migden MR et al (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa1805131 CrossRef

37.

Behshad R, Garcia-Zuazaga J, Bordeaux JS (2011) Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature. Br J Dermatol 165(6):1169–1177PubMedCrossRef

38.

Guthrie TH Jr. et al (1990) Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 8(2):342–346PubMedCrossRef

39.

Sadek H et al (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5‑fluorouracil, and bleomycin. Cancer 66(8):1692–1696PubMedCrossRef

40.

Khansur T, Kennedy A (1991) Cisplatin and 5‑fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 67(8):2030–2032PubMedCrossRef

41.

Cartei G et al (2000) Oral 5‑fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23(2):181–184PubMedCrossRef

42.

Lippman SM et al (1992) 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84(4):235–241PubMedCrossRef

43.

Shin DM et al (2001) Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91(7):1316–1323PubMedCrossRef

44.

Nottage MK et al (2017) Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 39(4):679–683PubMedCrossRef

45.

Maubec E et al (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29(25):3419–3426PubMedCrossRef

46.

Lewis CM et al (2012) A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18(5):1435–1446PubMedPubMedCentralCrossRef

47.

Heath CH et al (2013) Phase I study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys 85(5):1275–1281PubMedCrossRef

48.

Jenni D et al (2016) A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open. https://doi.org/10.1136/esmoopen-2015-000003 PubMedPubMedCentralCrossRef

49.

Wiegell SR, Petersen B, Wulf HC (2016) Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp: a randomized clinical trial. Br J Dermatol 174(5):979–984PubMedCrossRef

50.

Rowe DE, Carroll RJ, Day CL Jr. (1992) Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 26(6):976–990PubMedCrossRef

51.

Pickering CR et al (2014) Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20(24):6582–6592PubMedPubMedCentralCrossRef

52.

Leiter U et al (2016) Kutanes Plattenepithelkarzinom. Hautarzt 67(11):857–866PubMedCrossRef

53.

Nissen CV et al (2017) Pretreatment with 5‑fluorouracil cream enhances the efficacy of daylight-mediated photodynamic therapy for actinic keratosis. Acta Derm Venereol 97(5):617–621PubMedCrossRef

54.

Hitt R et al (2012) Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23(4):1016–1022PubMedCrossRef

55.

Vermorken JB et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127PubMedCrossRef

56.

Seiwert TY et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965PubMedCrossRef

57.

Fachgesellschaften, A.d.W.M., S3-Leitlinie, Prävention von Hautkrebs 2014.

58.

Chen AC et al (2015) A phase 3 randomized trial of Nicotinamide for skin-cancer chemoprevention. N Engl J Med 373(17):1618–1626PubMedCrossRef

Titel: Plattenepithelkarzinom der Haut
verfasst von: Andreas Meiwes
Prof. Dr. Ulrike Leiter
Publikationsdatum: 14.07.2019
Verlag: Springer Medizin
Schlagwörter: Plattenepithelkarzinom der Haut
Plattenepithelkarzinom der Haut
Cetuximab
Erschienen in: Die Onkologie / Ausgabe 9/2019
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-019-0620-3

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Plattenepithelkarzinom der Haut

Zusammenfassung

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Geriatrisches Assessment bei älteren hämatologischen Patienten

Ältere Patienten in der onkologischen Rehabilitation

Kolorektales Karzinom: MSI-Analyse sollte zum Standard gehören

Erfassung von Gebrechlichkeit bei betagten Patienten in der Radioonkologie

Besonderheiten der onkologischen Chirurgie beim alten Patienten

Ein besonderer Behandlungsauftrag: Geriatrische Tumorpatienten palliativ versorgen

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie